Preoperative Diagnostic Challenges in Patients Being Evaluated for Resection of Pancreatic Serous Cystadenomas

Serous cystadenomas (SCAs) are benign pancreatic cystic neoplasms for which surveillance can be safely discontinued once the diagnosis is established with confidence. However, distinguishing SCAs from premalignant or malignant pancreatic cystic lesions remains challenging despite advances in cross-sectional imaging and endoscopic ultrasound (EUS), resulting in unnecessary pancreatic resection. We performed a retrospective review of all pancreatic resections performed at a single tertiary referral center between January 2010 and December 2022 to identify patients with a final pathological diagnosis of SCA. Demographic, radiographic, operative, and postoperative outcomes were analyzed. Among 556 pancreatic resections, 20 patients (4%) had pathologically confirmed SCAs. The median age was 62 years, 55% were women, and the median cyst size was 3.0 cm. Surgery was performed because malignancy could not be excluded in 40% of patients, concern for a mucinous cystic neoplasm in 35%, and interval cyst growth in 25%. Sixteen patients (80%) underwent preoperative EUS with fine-needle aspiration, but cytology was frequently nondiagnostic and neither confirmed SCA nor reliably excluded a mucinous lesion. Seven patients underwent pancreaticoduodenectomy and 13 underwent distal pancreatectomy. Postoperative morbidity occurred in 50% of patients, including clinically relevant postoperative pancreatic fistula in 30%, with no disease-specific mortality. These findings demonstrate that pancreatic resection for SCAs is driven primarily by persistent diagnostic uncertainty rather than symptoms or malignant potential. Despite contemporary imaging and EUS, confidently differentiating SCAs from premalignant or malignant pancreatic cystic neoplasms remains difficult. Improved diagnostic strategies, including molecular testing and enhanced risk stratification, may reduce unnecessary pancreatic resection while preserving oncologic safety.

Authors

Institutions

Publication Details

Journal
The American Surgeon
Published
2026-10-07
DOI
https://doi.org/10.1177/00031348261496002
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Preoperative Diagnostic Challenges in Patients Being Evaluated for Resection of Pancreatic Serous Cystadenomas

Pejman Radkani, Shekhar Gogna, Brian Nguyen, Dimitrios Moris et al.
The American Surgeon
Pancreatic and Hepatic Oncology Research
article

Preoperative Diagnostic Challenges in Patients Being Evaluated for Resection of Pancreatic Serous Cystadenomas

Pejman Radkani, Shekhar Gogna, Brian Nguyen, Dimitrios Moris, Matthew Luckman, Vasalya Panchumarthi, David Walls, Emily Winslow, Piyush Gupta, Thomas Fishbein
article en

Abstract

Serous cystadenomas (SCAs) are benign pancreatic cystic neoplasms for which surveillance can be safely discontinued once the diagnosis is established with confidence. However, distinguishing SCAs from premalignant or malignant pancreatic cystic lesions remains challenging despite advances in cross-sectional imaging and endoscopic ultrasound (EUS), resulting in unnecessary pancreatic resection. We performed a retrospective review of all pancreatic resections performed at a single tertiary referral center between January 2010 and December 2022 to identify patients with a final pathological diagnosis of SCA. Demographic, radiographic, operative, and postoperative outcomes were analyzed. Among 556 pancreatic resections, 20 patients (4%) had pathologically confirmed SCAs. The median age was 62 years, 55% were women, and the median cyst size was 3.0 cm. Surgery was performed because malignancy could not be excluded in 40% of patients, concern for a mucinous cystic neoplasm in 35%, and interval cyst growth in 25%. Sixteen patients (80%) underwent preoperative EUS with fine-needle aspiration, but cytology was frequently nondiagnostic and neither confirmed SCA nor reliably excluded a mucinous lesion. Seven patients underwent pancreaticoduodenectomy and 13 underwent distal pancreatectomy. Postoperative morbidity occurred in 50% of patients, including clinically relevant postoperative pancreatic fistula in 30%, with no disease-specific mortality. These findings demonstrate that pancreatic resection for SCAs is driven primarily by persistent diagnostic uncertainty rather than symptoms or malignant potential. Despite contemporary imaging and EUS, confidently differentiating SCAs from premalignant or malignant pancreatic cystic neoplasms remains difficult. Improved diagnostic strategies, including molecular testing and enhanced risk stratification, may reduce unnecessary pancreatic resection while preserving oncologic safety.

The American Surgeon
University of Wisconsin System (US), Georgetown University (US), MedStar Georgetown University Hospital (US)
Openalex Percentile: Top 16%
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.